Thursday, September 02, 2010

Lung Cancer

APRiCOT-L
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination with Erlotinib in Non-Small Cell Lung Cancer Patients
E1505
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB - IIIA Non-Small Cell Lung Cancer (NSCLC)

We participate in many NCI sponsored trials. Please feel free to contact Leann Ross at (304) 399-6617 or leann.ross@chhi.org or Barbara Payne at (304) 399-6637.

For more information about the clinical trials listed please go to http://www.clinicaltrials.gov/.